


<b>Name</b>	Seung Hyeun Lee (MD, PhD)	
<b>Country</b>	Republic of Korea	
<b>Organization</b>	Kyung Hee University Hospital	
<b>Current Position</b>	Associate Professor	

### Educational Background

1996.Mar ~ 2002.Feb	MD Degree, Korea University College of Medicine
2004.Sep ~ 2006.Aug	Master's Degree, Internal Medicine, Korea University Graduate School
2006.Sep ~ 2012.Aug	PhD Degree, Internal Medicine, Korea University Graduate School

### Professional Experiences

2002.Mar ~ 2003.Feb	Internship, Internal Medicine, Korea University Anam Hospital
2003.Mar ~ 2007.Feb	Residency, Internal Medicine, Korea University Anam Hospital
2007.May ~ 2010.Apr	Military service as a public health doctor
2010.May ~ 2012.Apr	Clinical Instructor, Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Anam Hospital
2012.Mar ~ 2013.Feb	Clinical Assistant Professor, Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Anam Hospital
2013.Mar ~ 2016.Feb	Head of Division, Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, KEPCO Medical Center
2016.Mar ~ 2020.Feb	Assistant Professor, Department of Internal Medicine, Kyung Hee University Medical Center
2020.Mar ~ Present	Associate Professor, Department of Internal Medicine, Kyung Hee University Medical Center

### Professional Organizations

Korean Association of Internal Medicine (2002~)
Korean Academy of Tuberculosis and Respiratory Diseases (2006~)
Korean Association for Lung Cancer (2010~)
Korean Cancer Association (2014~)
American Thoracic Society (2012~)
International Association for the Study of Lung Cancer (2015~)
American Association of Cancer Research (2019~)

---

### Main Scientific Publications

1. Quantitative proteomic analysis of bronchoalveolar lavage fluids from patients with small cell lung cancers; *Proteomics-Clinical Applications*, Mar, 2023 (IF 3.60)
  2. Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer; *Cancer Research and Treatment*, Jan, 2023 (IF 5.03)
  3. Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis; *Onco Targets Ther.* 2022 (IF 4.37)
  4. High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy; *Biomedicines*, 2022 (IF 4.73)
  5. Overexpression of Reactive Oxygen Species Modulator 1 Predicts Unfavorable Clinical Outcome in EGFR-Mutant Lung Adenocarcinomas Treated With Targeted Therapy, *Front. Oncol.* 2021;11,770230 (IF 6.224)
  6. Serum Reactive Oxygen Species Modulator 1 as a Novel Predictive Biomarker for Resected Lung Adenocarcinoma: A Retrospective Pilot Study; *Onco Targets Ther.* 2021 Oct 21;14:5097-5106 (IF 4.14)
  7. Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum-based doublet chemotherapy and immunotherapy (SPACE study); *Thorac Cancer.* 2021 Apr;12(8):1264-1268 (IF 3.50)
  8. Primary Resistance to Immune Checkpoint Blockade in an STK11/TP53/KRAS- Mutant Lung Adenocarcinoma with High PD-L1 Expression; *Onco Targets Ther.* 2020 Sep 7;13:8901-8905 (IF 3.34)
-